Quest Diagnostics (DGX) Tops Q1 EPS by 5c; offers guidance

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.21, $0.05 better than the analyst estimate of $2.16. Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.64 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.55-$9.80, versus the consensus of $9.69. Quest Diagnostics sees FY2025 revenue of $10.7-10.85 billion, versus the consensus of $10.78 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue
• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial